Moderna (MRNA) Projected to Post Earnings on Thursday

Moderna (NASDAQ:MRNA - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Moderna to post earnings of ($2.90) per share and revenue of $130.35 million for the quarter.

Moderna Trading Up 1.3 %

MRNA stock traded up $0.36 during trading hours on Tuesday, hitting $27.82. 5,238,914 shares of the stock were exchanged, compared to its average volume of 7,367,876. The firm has a market capitalization of $10.76 billion, a P/E ratio of -3.00 and a beta of 2.23. The company has a 50-day simple moving average of $29.91 and a two-hundred day simple moving average of $38.08. Moderna has a 12 month low of $23.15 and a 12 month high of $170.47.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. UBS Group reduced their target price on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Finally, Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.